Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis.


Journal

Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278

Informations de publication

Date de publication:
05 2020
Historique:
received: 16 01 2020
revised: 30 03 2020
accepted: 31 03 2020
pubmed: 26 4 2020
medline: 20 4 2021
entrez: 26 4 2020
Statut: ppublish

Résumé

To quantify peripheral nerve lesions in symptomatic and asymptomatic hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PNP) by analyzing the magnetization transfer ratio (MTR) of the sciatic nerve, and to test its potential as a novel biomarker for macromolecular changes. Twenty-five patients with symptomatic ATTRv-PNP, 30 asymptomatic carriers of the mutant transthyretin gene (mutTTR), and 20 age-/sex-matched healthy controls prospectively underwent magnetization transfer contrast imaging at 3 Tesla. Two axial three-dimensional gradient echo sequences with and without an off-resonance saturation rapid frequency pulse were conducted at the right distal thigh. Sciatic nerve regions of interest were manually drawn on 10 consecutive axial slices in the images without off-resonance saturation, and then transferred to the corresponding slices that were generated by the sequence with the off-resonance saturation pulse. Subsequently, the MTR and cross-sectional area (CSA) of the sciatic nerve were evaluated. Detailed neurologic and electrophysiologic examinations were conducted in all ATTRv-PNP patients and mutTTR-carriers. Sciatic nerve MTR and CSA reliably differentiated between ATTRv-PNP, mutTTR-carriers, and controls. MTR was lower in ATTRv-PNP (26.4 ± 0.7; P < 0.0001) and in mutTTR-carriers (32.6 ± 0.8; P = 0.0005) versus controls (39.4 ± 2.1), and was also lower in ATTRv-PNP versus mutTTR-carriers (P = 0.0009). MTR correlated negatively with the NIS-LL and positively with CMAPs and SNAPs. CSA was higher in ATTRv-PNP (34.3 ± 1.7 mm MTR is a novel imaging marker that can quantify macromolecular changes in ATTRv-PNP and differentiate between symptomatic ATTRv-PNP and asymptomatic mutTTR-carriers and correlates with electrophysiology.

Identifiants

pubmed: 32333729
doi: 10.1002/acn3.51049
pmc: PMC7261747
doi:

Substances chimiques

Biomarkers 0
Prealbumin 0
TTR protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

799-807

Informations de copyright

© 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Références

Magn Reson Med. 1989 Apr;10(1):135-44
pubmed: 2547135
Radiology. 2019 Jul;292(1):149-156
pubmed: 31063079
J Neurol. 2014 Dec;261(12):2429-37
pubmed: 25270680
Neurology. 1999;53(5 Suppl 3):S29-32
pubmed: 10496208
Clin Neuroradiol. 2015 Oct;25 Suppl 2:283-9
pubmed: 26070607
J Magn Reson Imaging. 2009 Apr;29(4):982-6
pubmed: 19306447
Brain. 1974 Jun;97(2):395-406
pubmed: 4373122
Ann Neurol. 2017 Nov;82(5):676-685
pubmed: 29023976
Neurology. 1984 Aug;34(8):1025-32
pubmed: 6087202
Brain. 2015 Mar;138(Pt 3):549-62
pubmed: 25526974
Muscle Nerve. 2012 Jan;45(1):13-7
pubmed: 22190300
J Peripher Nerv Syst. 2019 Dec;24(4):314-319
pubmed: 31583784
Curr Opin Neurol. 2017 Oct;30(5):481-489
pubmed: 28678039
Neurology. 1999;53(5 Suppl 3):S3-7
pubmed: 10496203
Ann Neurol. 1999 Nov;46(5):747-54
pubmed: 10553992
Neurology. 2014 Feb 18;82(7):598-606
pubmed: 24415574
Brain. 2006 Aug;129(Pt 8):2008-16
pubmed: 16815879
Neurology. 2001 Feb 27;56(4):431-5
pubmed: 11261421
Mult Scler. 2012 Aug;18(8):1125-34
pubmed: 22194217
Magn Reson Imaging. 1998 Nov;16(9):1033-41
pubmed: 9839987
J Magn Reson Imaging. 2013 May;37(5):1234-7
pubmed: 23023888
Mult Scler. 2013 Feb;19(2):241-4
pubmed: 22492133
Lancet Neurol. 2011 Dec;10(12):1086-97
pubmed: 22094129
Neurology. 1998 Sep;51(3):708-14
pubmed: 9748014
J Neurol. 2017 Jul;264(7):1434-1443
pubmed: 28620719
NMR Biomed. 2001 Apr;14(2):57-64
pubmed: 11320533
Neurology. 2018 Aug 14;91(7):e625-e634
pubmed: 30030328
Neurology. 2014 Oct 21;83(17):1545-53
pubmed: 25253751
J Neurosurg. 2019 May 24;:1-5
pubmed: 31125966
Neurology. 2017 Jun 13;88(24):2302-2309
pubmed: 28500227
Neurology. 1999;53(5 Suppl 3):S46-8
pubmed: 10496211
Eur Neurol. 1999;41 Suppl 1:8-13
pubmed: 10023123
N Engl J Med. 2018 Jul 05;379(1):22-31
pubmed: 29972757
Ann Neurol. 2008 Feb;63(2):254-62
pubmed: 18257039
Nat Clin Pract Neurol. 2005 Nov;1(1):45-53
pubmed: 16932491
Nat Rev Neurol. 2018 Oct;14(10):577-589
pubmed: 30171200
Neurology. 2017 Aug 1;89(5):475-484
pubmed: 28679600
PLoS One. 2014 Mar 13;9(3):e91098
pubmed: 24625687
Invest Radiol. 2018 Jul;53(7):397-402
pubmed: 29470194
N Engl J Med. 2018 Jul 5;379(1):11-21
pubmed: 29972753
Neurology. 2007 Aug 14;69(7):693-8
pubmed: 17698792
Neuroimage. 2013 Feb 1;66:103-9
pubmed: 23110887
Neurology. 1999;53(5 Suppl 3):S12-7
pubmed: 10496205
Neurology. 2012 Aug 21;79(8):785-92
pubmed: 22843282
Ann Neurol. 2017 Jun;81(6):857-870
pubmed: 28512753
Ann Neurol. 2015 Dec;78(6):939-48
pubmed: 26381658

Auteurs

Jennifer Kollmer (J)

Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
Amyloidosis Center Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.

Ute Hegenbart (U)

Amyloidosis Center Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.
Medical Department V, Heidelberg University Hospital, Heidelberg, Germany.

Christoph Kimmich (C)

Amyloidosis Center Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.
Medical Department V, Heidelberg University Hospital, Heidelberg, Germany.

Ernst Hund (E)

Amyloidosis Center Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.
Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.

Jan C Purrucker (JC)

Amyloidosis Center Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.
Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.

John M Hayes (JM)

Department of Neurology, University of Michigan, Ann Arbor, MI.

Stephen I Lentz (SI)

Department of Internal Medicine, Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI.

Georges Sam (G)

Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.

Johann M E Jende (JME)

Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.

Stefan O Schönland (SO)

Amyloidosis Center Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.
Medical Department V, Heidelberg University Hospital, Heidelberg, Germany.

Martin Bendszus (M)

Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.

Sabine Heiland (S)

Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
Division of Experimental Radiology, Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.

Markus Weiler (M)

Amyloidosis Center Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.
Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH